碳酸氢钠输注对代谢性酸中毒脓毒症患者死亡率的影响
该研究利用MIMIC-III数据库纳入1718例代谢性酸中毒的脓毒症患者,其中500例接受碳酸氢钠(SB)输注、1218例未接受,采用倾向评分及边际结构Cox模型调整混杂。总体人群中SB与死亡率无显著相关(HR 1.04;95%CI 0.86-1.26;p=0.67),但在AKI 2或3期且pH<7.2的患者中SB与生存改善相关(HR 0.74;95%CI 0.51-0.86;p=0.021),边际结构Cox模型重复出相似结果。作者结论认为SB输注总体上未改善结局,但在AKI 2或3期合并严重酸中毒的脓毒症患者中与生存改善相关,结果需随机对照试验验证。
要点
- 总体代谢性酸中毒脓毒症人群中,SB组与非SB组死亡率无显著差异(HR 1.04;95%CI 0.86-1.26;p=0.67)。
- AKI 2或3期且pH<7.2的脓毒症患者中,SB输注与生存改善相关(HR 0.74;95%CI 0.51-0.86;p=0.021)。
- SB组基线pH 7.16(SD 0.10)低于非SB组7.22(SD 0.07),碳酸氢根11.84(SD 3.63)mmol/l低于非SB组14.88(SD 3.36)mmol/l,均p<0.001。
- 边际结构Cox模型调整基线与时间变化混杂后重复出相似结果。
- 作者结论认为结果需随机对照试验验证。
适用人群与场景
- 来自MIMIC-III数据库的代谢性酸中毒脓毒症患者,共1718例,其中SB组500例、非SB组1218例。
研究设计与关键结果
- 研究类型为基于MIMIC-III数据库的分析,纳入1718例代谢性酸中毒脓毒症患者,SB组500例、非SB组1218例,采用倾向评分及边际结构Cox模型调整混杂。
- 总体人群SB与非SB组死亡率无显著差异(HR 1.04;95%CI 0.86-1.26;p=0.67)。
- AKI 2或3期且pH<7.2的患者中,SB输注与生存改善相关(HR 0.74;95%CI 0.51-0.86;p=0.021)。
- SB组基线pH 7.16(SD 0.10)vs 非SB组7.22(SD 0.07),p<0.001;SB组碳酸氢根11.84(SD 3.63)mmol/l vs 非SB组14.88(SD 3.36)mmol/l,p<0.001。
- 边际结构Cox模型重复出相似结果。
证据类型、等级与局限
- 证据类型为基于MIMIC-III数据库的分析(研究论文)。
- 局限:原文未报告局限性。
- 作者结论认为结果需随机对照试验验证。
对床旁实践的改变
- 在代谢性酸中毒的脓毒症患者中,SB输注总体上未与死亡率改善相关(HR 1.04;95%CI 0.86-1.26;p=0.67)。
- 在AKI 2或3期且pH<7.2的脓毒症患者中,SB输注与生存改善相关(HR 0.74;95%CI 0.51-0.86;p=0.021)。
- 作者认为该结果需随机对照试验验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Although sodium bicarbonate (SB) solution has been widely used in clinical practice, its effect on mortality when administered to a large population of patients with acidosis is not known. The study aimed to investigate the effectiveness of SB infusion in septic patients with metabolic acidosis.
METHODS: Septic patients with metabolic acidosis were identified from the Medical Information Mart for Intensive Care (MIMIC)-III database. Propensity score (PS) was used to account for the baseline differences in the probability to receive SB or not. The marginal structural Cox model (MSCM) was employed to adjust for both baseline and time-varying confounding factors.
MAIN RESULTS: A total of 1718 septic patients with metabolic acidosis were enrolled in the study, including 500 in the SB group and 1218 in the non-SB group. Both pH [7.16 (standard deviation (SD): 0.10) vs. 7.22 (SD: 0.07); p < 0.001] and bicarbonate concentration (BC) [11.84 (SD: 3.63) vs. 14.88 (SD: 3.36) mmol/l; p < 0.001] were significantly lower in the SB than that in the non-SB group. While there was no significant mortality effect in the overall population [hazard ratio (HR): 1.04; 95% CI 0.86-1.26; p = 0.67], SB was observed to be beneficial in patients with acute kidney injury (AKI) stage 2 or 3 and pH < 7.2 (HR 0.74; 95% CI 0.51-0.86; p = 0.021). Similar results were replicated with the MSCM.
CONCLUSION: Our study observed that SB infusion was not associated with improved outcome in septic patients with metabolic acidosis, but it was associated with improved survival in septic patients with AKI stage 2 or 3 and severe acidosis. The results need to be verified in randomized controlled trials.
参考来源
- Zhang Z, Zhu C, Mo L, et al. Effectiveness of sodium bicarbonate infusion on mortality in septic patients with metabolic acidosis. Intensive Care Med. 2018. PMID: 30255318. doi:10.1007/s00134-018-5379-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。